已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice (S9.007)

奥图穆马 药理学 医学 脾脏 奥克列珠单抗 效力 CD20 流式细胞术 局部淋巴结试验 药代动力学 免疫学 化学 淋巴瘤 体外 生物化学 美罗华 敏化 皮肤致敏
作者
Marc Bigaud,Daniel C. Anthony,Géraldine Zipfel,Tatjana Uffelmann,Helena Vostiarova,Volker Engelhardt,Barbara Nuesslein‐Hildesheim,Bernd C. Kieseier
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:100 (17_supplement_2) 被引量:1
标识
DOI:10.1212/wnl.0000000000203420
摘要

Objective:

Benchmark the potency of subcutaneous ofatumumab (OMB-sc) and intravenous ocrelizumab (OCR-iv) at depleting B cells expressing human CD20 in transgenic mice.

Background:

Therapies that deplete CD20-positive B cells are effective in multiple sclerosis. Pilot work has suggested improved lymph node (LN) targeting for OMB-sc vs OCR-iv.

Design/Methods:

Humanized CD20 mice (C57BL/6-Ms4a1tm2[hCD20]Smoc) were treated once with OMB-sc or OCR-iv at various doses. Drug levels and B-cell counts were assessed via IgG-binding ELISA and flow cytometry, respectively, in blood and lymphoid organs (spleen, inguinal LNs, bone marrow [BM]).

Results:

Dose-proportional drug levels with B-cell depletion in all compartments was noted for both therapies. Three days post treatment, serum levels needed to achieve 50%/90% (EC50/EC90) efficacy were ~0.01/0.3 mg/mL, respectively, with OMB-sc and ~0.2/5.0 mg/mL, respectively, with OCR-iv, indicative of 20-fold higher B-cell–depleting potency for OMB-sc. OMB-sc reached its EC50 at the human-equivalent dose (huD) of 6 mg per mouse; OCR-iv was ~40-fold above its EC90 at the huD (200 mg). Drug level ratios (spleen and LN vs serum) were 5–20 for OMB-sc and ≤1 for OCR-iv, confirming lymphoid organ targeting for OMB-sc. Both treatments appeared equipotent at depleting noncirculating B cells (EC50s ~−0.2 mg/mL). Marginal zone and follicular B cells in secondary lymphoid organs were markedly depleted by OCR-iv but spared by OMB-sc at the huD. OMB-sc achieved drug levels 10-fold below the EC50 in BM at the huD, whereas OCR-iv reached its EC90, which suggests a lower impact on BM-resident CD20-expressing cells with OMB-sc

Conclusions:

OMB-sc demonstrated better efficiency in targeting lymphoid organs and greater potency for depleting circulating B cells vs OCR-iv. A sparing effect regarding marginal zone and follicular B cells was demonstrated with OMB-sc. OMB-sc may offer high efficacy and lower long-term safety risks with convenient dosing vs OCR-iv in humans. Disclosure: Marc Bigaud has received personal compensation for serving as an employee of Novartis Pharma. Dr. Anthony has received personal compensation for serving as an employee of University of Oxford. Dr. Anthony has received personal compensation for serving as an employee of Somerville College Oxford. Dr. Anthony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Anthony has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroplast. Dr. Anthony has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Oxomics. The institution of Dr. Anthony has received research support from Numares. The institution of Dr. Anthony has received research support from MRC UK. Mrs. Zipfel has nothing to disclose. Tatjana Uffelmann has nothing to disclose. Mrs. Vostiarova has nothing to disclose. Mr. Engelhardt has nothing to disclose. Dr. Nuesslein-Hildesheim has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Nuesslein-Hildesheim has stock in Novartis Pharma AG. Bernd C. Kieseier, MD has nothing to disclose.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dominic12361发布了新的文献求助10
刚刚
潇潇雨歇发布了新的文献求助10
1秒前
深情安青应助xin采纳,获得10
1秒前
1秒前
Rhythm发布了新的文献求助10
2秒前
Devil发布了新的文献求助10
3秒前
Dr_ZHONG发布了新的文献求助30
3秒前
李爱国应助细心盼晴采纳,获得10
3秒前
彭于晏应助LJJ采纳,获得10
3秒前
完美的小凝完成签到 ,获得积分10
6秒前
8秒前
机智的小帅哥完成签到,获得积分10
9秒前
今后应助黄卡卡采纳,获得10
9秒前
9秒前
领导范儿应助zz采纳,获得10
11秒前
11秒前
sweet驳回了小鱼应助
11秒前
11秒前
12秒前
慕青应助廖书香采纳,获得10
12秒前
12秒前
13秒前
13秒前
YvonneL发布了新的文献求助10
13秒前
嘎嘎发布了新的文献求助10
14秒前
3210592完成签到,获得积分10
15秒前
ninomae发布了新的文献求助10
16秒前
形心1431发布了新的文献求助10
16秒前
小二郎应助anmds采纳,获得30
17秒前
冷静尔芙发布了新的文献求助10
18秒前
思源应助小城故事和冰雨采纳,获得10
18秒前
所所应助yunyun采纳,获得10
19秒前
YvonneL完成签到,获得积分20
20秒前
20秒前
WIN发布了新的文献求助10
21秒前
年轻馒头完成签到 ,获得积分10
21秒前
钟梦萍关注了科研通微信公众号
23秒前
25秒前
在水一方应助龙羽者采纳,获得10
25秒前
wangsenyu完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
SOFT MATTER SERIES Volume 22 Soft Matter in Foods 1000
Zur lokalen Geoidbestimmung aus terrestrischen Messungen vertikaler Schweregradienten 1000
Rapid synthesis of subnanoscale high-entropy alloys with ultrahigh durability 666
Selected research on camelid physiology and nutrition 500
《2023南京市住宿行业发展报告》 500
Architectural Corrosion and Critical Infrastructure 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4888162
求助须知:如何正确求助?哪些是违规求助? 4172807
关于积分的说明 12950670
捐赠科研通 3933806
什么是DOI,文献DOI怎么找? 2158530
邀请新用户注册赠送积分活动 1176733
关于科研通互助平台的介绍 1081100